PetVivo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
February 12, 2024 at 04:26 pm EST
Share
PetVivo Holdings, Inc. reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was USD 0.595891 million compared to USD 0.510109 million a year ago. Net loss was USD 1.75 million compared to USD 2.31 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.23 a year ago. Diluted loss per share from continuing operations was USD 0.12 compared to USD 0.23 a year ago.
For the nine months, sales was USD 0.92044 million compared to USD 0.791563 million a year ago. Net loss was USD 8.3 million compared to USD 6.39 million a year ago. Basic loss per share from continuing operations was USD 0.64 compared to USD 0.64 a year ago. Diluted loss per share from continuing operations was USD 0.64 compared to USD 0.64 a year ago.
PetVivo Holdings, Inc. is a biomedical device company. The Company is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for animals. The Companyâs lead product Spryng with OsteoCushion Technology, is a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals, such as dogs and horses. Its products are derived from biomaterials that simulate a bodyâs cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions, which incorporate such tissue building blocks as collagen, elastin, and proteoglycans such as heparin. The Company has a pipeline of therapeutic devices for both veterinary and human clinical applications.
PETVIVO HOLDINGS, INC. 
